American College of Clinical Pharmacy
      Search      Cart
         

2024 Geriatric Lit Study: Module 1A-B (Recert)


Member Price:
$60.00
Nonmember Price:
$115.00
ASHP members, please call (913)492-3311 to recieve member pricing. Your ASHP membership number and expiration date are required.

ACCP collaborates with ASHP on Geriatric Pharmacy activities.

 

ASHP members, please visit www.rxcertifications.org to receive member pricing.

 

 

Product Overview

The Literature Study Module provides immediate access to peer-selected, contemporary articles that are relevant to specialty practice. After learners review the content, they must successfully complete an online assessment to earn recertification credit.

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities. Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice.

Module 1A: Cardiovascular and Osteoporosis
This module focuses on 2023 guidelines for chronic coronary disease, diuretic comparison and cardiovascular events, anticoagulant use and dementia, and 2023 osteoporosis guidelines.

Module 1B: Safety, Dementia, and Depression
This module focuses on 2023 Beers Criteria, STOPP/START criteria, glucose-lowering drugs and dementia, and treatment-resistant depression in the geriatric population.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ACCP and ASHP professional development program for BCGP recertification approved by BPS.

Release Date: July 17, 2024
BCGP Deadline: July 15, 2025
ACPE Deadline: July 17, 2027

Publication Year: 2024
Format: Published Articles with Test for Recertification Credit

Technical Requirements:

Contents

Module 1A: Cardiovascular and Osteoporosis

This module focuses on 2023 guidelines for chronic coronary disease, diuretic comparison and cardiovascular events, anticoagulant use and dementia, and 2023 osteoporosis guidelines. 

Module 1B: Safety, Dementia, and Depression

This module focuses on 2023 Beers Criteria, STOPP/START criteria, glucose-lowering drugs and dementia, and treatment-resistant depression in the geriatric population. 

CPE Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are approved by BPS as a provider for the recertification of of BCGP.

BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/

To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.

The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.

In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.

The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.

Target Audience: These Literature Studies are designed to help board-certified pharmacists who are seeking recertification credit hours to maintain their Board of Pharmacy Specialties (BPS) Certification.

Contents

Module 1A: Cardiovascular and Osteoporosis

Activity Number: 0204-9999-24-950-H01-P
Contact Hour(s): 5.00
Activity Type: Application Based

Learning Objectives

Article: Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9-e119. doi: 10.1161/CIR.0000000000001168. Epub 2023 Jul 20. PMID: 37471501.

Learning Objectives:

  • Describe the multiorganizational guideline for the management of patients with chronic coronary disease (CCD) from the American Heart Association (AHA)/American College of Cardiology (ACC) Joint Committee on Clinical Practice Guidelines
  • Develop recommendations for the management of patients with chronic coronary disease 

Article: Ishani A, Cushman WC, Leatherman SM, et al. Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. N Engl J Med. 2022 Dec 29;387(26):2401-2410. doi: 10.1056/NEJMoa2212270. Epub 2022 Dec 14. PMID: 36516076.

Learning Objectives:  

  • Describe the study by Ishani and colleagues comparing the efficacy of chlorthalidone with hydrochlorothiazide for reducing the risk of cardiovascular disease in older adults with hypertension
  • Develop recommendations for the use of thiazide diuretics for reducing the risk of cardiovascular disease in older adults with hypertension

Article: Ouellet GM, O'Leary JR, Leggett CG, et al. Benefits and harms of oral anticoagulants for atrial fibrillation in nursing home residents with advanced dementia. J Am Geriatr Soc. 2023;71(2): 561-568. doi:10.1111/jgs.18108

Learning Objectives:  

  • Describe the study by Ouellet and colleagues of oral anticoagulant use for stroke prevention in nursing home residents with atrial fibrillation (AF) and advanced dementia
  • Develop recommendations for the use of oral anticoagulants for stroke prevention in older adults with atrial fibrillation and advanced dementia  

Article: Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, et al. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023 Feb;176(2):224-238. doi: 10.7326/M22-1034. Epub 2023 Jan 3. Erratum in: Ann Intern Med. 2023 Jun;176(6):882-884. PMID: 36592456.

Learning Objectives:  

  • Describe the American College of Physicians (ACP) clinical guideline for pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults
  • Develop recommendations for the pharmacologic treatment of adults with primary osteoporosis or low bone mass to prevent fractures  

Module 1B: Safety, Dementia, and Depression

Activity Number: 0204-9999-24-951-H01-P
Contact Hour(s): 5.00
Activity Type: Application Based

Learning Objectives

Article: By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. doi: 10.1111/jgs.18372. Epub 2023 May 4. PMID: 37139824.

Learning Objectives:  

  • Describe the American Geriatrics Society (AGS) 2023 updated Beers Criteria® for potentially inappropriate medication use in older adults
  • Develop pharmacotherapy recommendations for older adults based on the American Geriatrics Society 2023 updated Beers Criteria® for potentially inappropriate medication use 

Article: O'Mahony D, Cherubini A, Guiteras AR, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3.  Eur Geriatr Med. 2023 Aug;14(4):625-632. doi: 10.1007/s41999-023-00777-y. Epub 2023 May 31. Erratum in: Eur Geriatr Med. 2023 Jun 16;: PMID: 37256475

Learning Objectives:

  • Describe version 3 of the STOPP/START criteria for older adults for potentially inappropriate prescribing (PIP)
  • Develop recommendations for older adults based on for the use of the STOPP/START criteria for potentially inappropriate prescribing  

Article: Tang H, Shao H, Shaaban CE, et al. Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies. J Am Geriatr Soc. 2023 Jul;71(7):2096-2106. doi: 10.1111/jgs.18306. Epub 2023 Feb 23. PMID: 36821780; PMCID: PMC10363181.

Learning Objectives:

  • Describe the systematic review and meta-analysis by Tang and colleagues of newer glucose-lowering drugs (sodium-glucose cotransporter [SGLT]-2 inhibitors, glucagon-like peptide [GLP]-1 receptor agonists, and dipeptidyl peptidase [DPP]-4 inhibitors) and the risk of dementia in adults with type 2 diabetes mellitus
  • Develop recommendations for the use of newer glucose-lowering drugs (sodium-glucose cotransporter [SGLT]-2 inhibitors, glucagon-like peptide [GLP]-1 receptor agonists, and dipeptidyl peptidase [DPP]-4 inhibitors) in adults with type 2 diabetes mellitus  

Article: Lockery JE, Collyer TA, Woods RL, et al. Potentially inappropriate medication use is associated with increased risk of incident disability in healthy older adults. J Am Geriatr Soc. 2023 Aug;71(8):2495-2505. doi: 10.1111/jgs.18353. Epub 2023 Apr 11. PMID: 37039393.

Learning Objectives:  

  • Describe the study by Lockery and colleagues of the impact of potentially inappropriate medication (PIM) use in healthy community-dwelling older adults
  • Develop recommendations for reducing potentially inappropriate medication use in healthy community-dwelling older adults  

Article: Lenze EJ, Mulsant BH, Roose SP, et al. Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. N Engl J Med. 2023 Mar 23;388(12):1067-1079. doi: 10.1056/NEJMoa2204462. Epub 2023 Mar 3. PMID: 36867173.

Learning Objectives:

  • Describe the Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM) study by Lenze and colleagues
  • Develop recommendations for the treatment of older adults with treatment-resistant depression 

Commercial Support

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.